Evidence map›Paper›PMID 42494592›Full record

ArticleFrontiers in oncology2026

Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review.

Fang Yang, Siyu Guo, Ping Li, Mengqi Yang, Xuan Wu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fang Yang *Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, China.
Siyu Guo *Department of Radiotherapy, Peking University Shenzhen Hospital, The First School of Clinical Medicine, Guangdong Medical University, Shenzhen, China.
Ping LiDepartment of Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
Mengqi YangDepartment of Radiotherapy, Peking University Shenzhen Hospital, Shenzhen, China.
Xuan WuDepartment of Oncology, Peking University Shenzhen Hospital, The First School of Clinical Medicine, Guangdong Medical University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary breast squamous cell carcinoma (PBSCC) with HER2-positive status is exceptionally rare, with fewer than 100 cases reported globally, and HER2 positivity occurring in only 5.8-7.1% of these cases. No established treatment standards exist for this entity. We present the case of a 43-year-old woman with HER2-positive PBSCC who exhibited a poor response to neoadjuvant TCHP therapy (Miller-Payne grade 2). Local recurrence occurred just 3 months after mastectomy. Second-line therapy with pyrotinib plus capecitabine provided 9 months of disease control before lung metastasis emerged. Subsequent molecular profiling revealed a

Indexed as

antigen lossbreast squamous cell carcinomaHER2 amplificationPIK3CA mutationprecision therapy

Identifiers

PMID42494592
PMCPMC13391319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.